VAIA
ENTA icon

Virtus Alternative Investment Advisers’s Enanta Pharmaceuticals ENTA Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-126
Closed -$5K – 76
2020
Q4 		$5K Sell
126
-122
-49% -$5.37K 0.07% 254
2020
Q3 		$11K Buy
248
+14
+6% +$678 0.2% 130
2020
Q2 		$12K Sell
234
-220
-48% -$11.4K 0.19% 232
2020
Q1 		$23K Buy
454
+310
+215% +$16.5K 0.32% 44
2019
Q4 		$9K Buy
+144
New +$8.93K 0.14% 106

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Virtus Alternative Investment Advisers's ENTA Position: Q1 2021 in Review

Virtus Alternative Investment Advisers sold out of Enanta Pharmaceuticals (ENTA) in Q1 2021, closing a stake of 126 shares — an estimated $5K sold.

Virtus Alternative Investment Advisers first reported a position in ENTA in Q4 2019 and held it in 5 quarters. The position peaked at $23K in Q1 2020. 148 funds tracked by Wall St. Rank hold ENTA as of Q1 2021.

  • Virtus Alternative Investment Advisers reported no remaining Enanta Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 126 Enanta Pharmaceuticals shares in Q1 2021, an estimated $5K.
  • Virtus Alternative Investment Advisers first reported a position in Enanta Pharmaceuticals in Q4 2019 and held it in 5 quarters.
  • Virtus Alternative Investment Advisers's Enanta Pharmaceuticals position peaked at $23K in Q1 2020.
  • 148 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2021.

Based on Virtus Alternative Investment Advisers's 13F filing for Q1 2021.